Skip to main content
Therapeutic DeliveryVolume 9, Issue 11, November 2018, Pages 811-821

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid(Article)

  Save all to author list
  • aBiotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia
  • bDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • cDepartment of Pharmacy, University of Novi Sad, Novi Sad, Serbia
  • dGroup for Nano and Flexible Electronics, Faculty of Technical Sciences, University of Novi Sad, Novi Sad, Serbia
  • eStem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia

Abstract

Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. β-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules. © 2018 Newlands Press.

Author keywords

deoxycholic acidmicroencapsulationprobucol

Indexed keywords

EMTREE drug terms:bile aciddeoxycholic acideudragitgamma interferonprobucolantidiabetic agentantioxidantdrug carriermethylmethacrylate-methacrylic acid copolymerpolymethacrylic acid derivativeprobucol
EMTREE medical terms:antioxidant activityArticlecell respirationcontrolled studycytokine releasedrug absorptiondrug formulationdrug releasedrug stabilityencapsulationmicrocapsuleNIT-1 cell lineoxidative stresspancreas islet beta cellparticle sizepriority journalanimalbioavailabilitycell linecell survivalchemical phenomenachemistrydrug effectmetabolismmicrocapsulemouseoral drug administrationpreclinical studyprocedures
MeSH:Administration, OralAnimalsAntioxidantsBiological AvailabilityCapsulesCell LineCell SurvivalDeoxycholic AcidDrug CarriersDrug CompoundingDrug Evaluation, PreclinicalDrug LiberationHydrophobic and Hydrophilic InteractionsHypoglycemic AgentsInsulin-Secreting CellsMiceOxidative StressPolymethacrylic AcidsProbucol

Chemicals and CAS Registry Numbers:

deoxycholic acid, 83-44-3; eudragit, 24938-16-7, 51822-44-7, 9065-11-6, 9010-88-2; gamma interferon, 82115-62-6; probucol, 23288-49-5;

Antioxidants; Capsules; Deoxycholic Acid; Drug Carriers; Hypoglycemic Agents; methylmethacrylate-methacrylic acid copolymer; Polymethacrylic Acids; Probucol

Manufacturers:

Drug manufacturer:

Sigma Aldrich, Australia

Funding details

Funding sponsor Funding number Acronym
Horizon 2020 Framework Programme
See opportunities by H2020		690876H2020
Horizon 2020 Framework Programme
See opportunities by H2020		H2020

  • 1

    The authors acknowledge use of Curtin laboratory equipment, scientific and technical assistance of Microscopy and Microanalysis Facility, which has been partially funded by the University, State and Commonwealth Governments. The work is partially supported by the European Union Horizon 2020 MEDLEM research project and innovation program under the Marie Skl-odowska-Curie (grant number 690876). The NIT-1 cells were a generous donation from G Morahan at the University of Western Australia. A-S Hani has been and is currently receiving of funding from Beijing Nat-Med Biotechnology Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

  • ISSN: 20415990
  • Source Type: Journal
  • Original language: English
  • DOI: 10.4155/tde-2018-0036
  • PubMed ID: 30444461
  • Document Type: Article
  • Publisher: Newlands Press Ltd

  Al-Salami, H.; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia;
© Copyright 2023 Elsevier B.V., All rights reserved.

Cited by 21 documents

Mooranian, A. , Ionescu, C.M. , Wagle, S.R.
Low-dose nano-gel incorporated with bile acids enhanced pharmacology of surgical implants
(2023) Therapeutic Delivery
Koh, W.L. , Foster, T. , Mooranian, A.
Applications of bile acids as biomaterials-based modulators, in biomedical science and microfluidics
(2022) Therapeutic Delivery
Kovacevic, B. , Ionescu, C.M. , Jones, M.
The Effect of Deoxycholic Acid on Chitosan-Enabled Matrices for Tissue Scaffolding and Injectable Nanogels
(2022) Gels
View details of all 21 citations
Inform me when this document is cited in Scopus:
Set citation alert Set citation feed
{"topic":{"name":"Bile Acid; Diabetes Mellitus; Beta Cell","id":73888,"uri":"Topic/73888","prominencePercentile":63.8726,"prominencePercentileString":"63.873","overallScholarlyOutput":0},"dig":"1039586ecade7f1a6ae7f9c89e3300c3f923889b863968f659b8a3db5e245d27"}

SciVal Topic Prominence

Topic:
Prominence percentile: